{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:16:22Z","timestamp":1770066982762,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"European Union\u2019s Seventh Framework Programme for research, technological development, and demonstration","award":["278981"],"award-info":[{"award-number":["278981"]}]},{"name":"Euro Bio-Imaging Project, Beaumont Hospital Cancer Research & Development Trust, The Company of Biologists and the Interdisciplinary Centre for Clinical Research M\u00fcnster (PIX)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00259-016-3343-3","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T12:33:27Z","timestamp":1458304407000},"page":"1673-1683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mechanistic interrogation of combination bevacizumab\/dual PI3K\/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers"],"prefix":"10.1007","volume":"43","author":[{"given":"Philip J.","family":"O\u2019Halloran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Viel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Wachsmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Schwegmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Kopka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika A.","family":"Jarzabek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Klasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sch\u00e4fers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen H. M.","family":"Prehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas H.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette T.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"3343_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396. doi: 10.1056\/NEJMoa043330 .","journal-title":"N Engl J Med"},{"key":"3343_CR2","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733\u201340. doi: 10.1200\/JCO.2008.19.8721 .","journal-title":"J Clin Oncol"},{"key":"3343_CR3","unstructured":"ClinicalTrials.gov. A study of Avastin\u00ae (BEVacizumab) in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. http:\/\/clinicaltrials.gov\/show\/NCT00943826 ."},{"key":"3343_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-008-9718-y","volume":"91","author":"RM Zuniga","year":"2009","unstructured":"Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91:329\u201336. doi: 10.1007\/s11060-008-9718-y .","journal-title":"J Neurooncol"},{"key":"3343_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/neuonc\/nop027","volume":"12","author":"JF Groot de","year":"2010","unstructured":"de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010;12:233\u201342. doi: 10.1093\/neuonc\/nop027 .","journal-title":"Neuro Oncol"},{"key":"3343_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","volume":"22","author":"KV Lu","year":"2012","unstructured":"Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex. Cancer Cell. 2012;22:21\u201335. doi: 10.1016\/j.ccr.2012.05.037 .","journal-title":"Cancer Cell"},{"key":"3343_CR7","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1073\/pnas.1014480108","volume":"108","author":"O Keunen","year":"2011","unstructured":"Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A. 2011;108:3749\u201354. doi: 10.1073\/pnas.1014480108 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3343_CR8","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1073\/pnas.89.7.2965","volume":"89","author":"AJ Wong","year":"1992","unstructured":"Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992;89:2965\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3343_CR9","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","volume":"8","author":"TJ Liu","year":"2009","unstructured":"Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 2009;8:2204\u201310. doi: 10.1158\/1535-7163.MCT-09-0160 .","journal-title":"Mol Cancer Ther"},{"key":"3343_CR10","unstructured":"ClinicalTrials.gov. Safety study of BEZ235 with everolimus in subjects with advanced solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01508104 ."},{"key":"3343_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1476-4598-10-90","volume":"10","author":"D Roulin","year":"2011","unstructured":"Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K\/mTOR inhibitor, in combination with sorafenib. Mol Cancer. 2011;10:90. doi: 10.1186\/1476-4598-10-90 .","journal-title":"Mol Cancer"},{"key":"3343_CR12","doi-asserted-by":"publisher","first-page":"e19592","DOI":"10.1371\/journal.pone.0019592","volume":"6","author":"RT Ullrich","year":"2011","unstructured":"Ullrich RT, Jikeli JF, Diedenhofen M, Bohm-Sturm P, Unruh M, Vollmar S, et al. In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS One. 2011;6:e19592. doi: 10.1371\/journal.pone.0019592 .","journal-title":"PLoS One"},{"key":"3343_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00259-013-2464-1","volume":"40","author":"T Viel","year":"2013","unstructured":"Viel T, Boehm-Sturm P, Rapic S, Monfared P, Neumaier B, Hoehn M, et al. Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI. Eur J Nucl Med Mol Imaging. 2013;40:1595\u2013606. doi: 10.1007\/s00259-013-2464-1 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3343_CR14","first-page":"996","volume":"46","author":"KP Schafers","year":"2005","unstructured":"Schafers KP, Reader AJ, Kriens M, Knoess C, Schober O, Schafers M. Performance evaluation of the 32-module quadHIDAC small-animal PET scanner. J Nucl Med. 2005;46:996\u20131004.","journal-title":"J Nucl Med"},{"key":"3343_CR15","volume-title":"VINCI - \u201cVolume Imaging in Neurological Research, Co-Registration and ROIs included","author":"S Vollmar","year":"2003","unstructured":"Vollmar S, Cizek J, Sue M, Klein J, Jacobs AH, Herholz K. VINCI - \u201cVolume Imaging in Neurological Research, Co-Registration and ROIs included. G\u00f6ttingen: Gesellschaft f\u00fcr wissenschaftliche Datenverarbeitung; 2003."},{"key":"3343_CR16","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1586\/ern.09.116","volume":"9","author":"NG Thaker","year":"2009","unstructured":"Thaker NG, Pollack IF. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother. 2009;9:1815\u201336. doi: 10.1586\/ern.09.116 .","journal-title":"Expert Rev Neurother"},{"key":"3343_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cncr.22741","volume":"110","author":"S Sathornsumetee","year":"2007","unstructured":"Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer. 2007;110:13\u201324. doi: 10.1002\/cncr.22741 .","journal-title":"Cancer"},{"key":"3343_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/neuonc\/nou040","volume":"16","author":"S Jalali","year":"2014","unstructured":"Jalali S, Chung C, Foltz W, Burrell K, Singh S, Hill R, et al. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro Oncol. 2014;16:868\u201379. doi: 10.1093\/neuonc\/nou040 .","journal-title":"Neuro Oncol"},{"key":"3343_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/jmri.22742","volume":"34","author":"C Lavini","year":"2011","unstructured":"Lavini C, Verhoeff JJ, Majoie CB, Stalpers LJ, Richel DJ, Maas M. Model-based, semiquantitative and time intensity curve shape analysis of dynamic contrast-enhanced MRI: a comparison in patients undergoing antiangiogenic treatment for recurrent glioma. J Magn Reson Imaging. 2011;34:1303\u201312. doi: 10.1002\/jmri.22742 .","journal-title":"J Magn Reson Imaging"},{"key":"3343_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.ijrobp.2013.04.029","volume":"86","author":"AR Cabrera","year":"2013","unstructured":"Cabrera AR, Cuneo KC, Desjardins A, Sampson JH, McSherry F, Herndon 2nd JE, et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys. 2013;86:873\u20139. doi: 10.1016\/j.ijrobp.2013.04.029 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3343_CR21","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/jmri.24513","volume":"40","author":"F Kording","year":"2014","unstructured":"Kording F, Weidensteiner C, Zwick S, Osterberg N, Weyerbrock A, Staszewski O, et al. Simultaneous assessment of vessel size index, relative blood volume, and vessel permeability in a mouse brain tumor model using a combined spin echo gradient echo echo-planar imaging sequence and viable tumor analysis. J Magn Reson Imaging. 2014;40:1310\u20138. doi: 10.1002\/jmri.24513 .","journal-title":"J Magn Reson Imaging"},{"key":"3343_CR22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/mrm.1910400602","volume":"40","author":"J Dennie","year":"1998","unstructured":"Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med. 1998;40:793\u20139.","journal-title":"Magn Reson Med"},{"key":"3343_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/mrm.24218","volume":"69","author":"B Lemasson","year":"2013","unstructured":"Lemasson B, Valable S, Farion R, Krainik A, Remy C, Barbier EL. In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology. Magn Reson Med. 2013;69:18\u201326. doi: 10.1002\/mrm.24218 .","journal-title":"Magn Reson Med"},{"key":"3343_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/nbm.1734","volume":"25","author":"N Pannetier","year":"2012","unstructured":"Pannetier N, Lemasson B, Christen T, Tachrount M, Tropres I, Farion R, et al. Vessel size index measurements in a rat model of glioma: comparison of the dynamic (Gd) and steady-state (iron-oxide) susceptibility contrast MRI approaches. NMR Biomed. 2012;25:218\u201326. doi: 10.1002\/nbm.1734 .","journal-title":"NMR Biomed"},{"key":"3343_CR25","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1212\/01.wnl.0000208958.29600.87","volume":"66","author":"WB Pope","year":"2006","unstructured":"Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258\u201360. doi: 10.1212\/01.wnl.0000208958.29600.87 .","journal-title":"Neurology"},{"key":"3343_CR26","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-10-1659","volume":"17","author":"T Fuereder","year":"2011","unstructured":"Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, et al. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K\/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res. 2011;17:5322\u201332. doi: 10.1158\/1078-0432.CCR-10-1659 .","journal-title":"Clin Cancer Res"},{"key":"3343_CR27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/OTT.S59314","volume":"7","author":"N Graf","year":"2014","unstructured":"Graf N, Li Z, Herrmann K, Weh D, Aichler M, Slawska J, et al. Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. Onco Targets Ther. 2014;7:789\u201398. doi: 10.2147\/OTT.S59314 .","journal-title":"Onco Targets Ther"},{"key":"3343_CR28","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/neuonc\/nos141","volume":"14","author":"RJ Harris","year":"2012","unstructured":"Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, et al. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol. 2012;14:1079\u201389. doi: 10.1093\/neuonc\/nos141 .","journal-title":"Neuro Oncol"},{"key":"3343_CR29","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/neuonc\/not216","volume":"16","author":"KM Schmainda","year":"2014","unstructured":"Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 2014;16:880\u20138. doi: 10.1093\/neuonc\/not216 .","journal-title":"Neuro Oncol"},{"key":"3343_CR30","doi-asserted-by":"publisher","first-page":"602812","DOI":"10.1155\/2011\/602812","volume":"2011","author":"S Nagpal","year":"2011","unstructured":"Nagpal S, Harsh G, Recht L. Bevacizumab improves quality of life in patients with recurrent glioblastoma. Chemother Res Pract. 2011;2011:602812. doi: 10.1155\/2011\/602812 .","journal-title":"Chemother Res Pract"},{"key":"3343_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11060-010-0117-9","volume":"99","author":"S Okubo","year":"2010","unstructured":"Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010;99:217\u201325. doi: 10.1007\/s11060-010-0117-9 .","journal-title":"J Neurooncol"},{"key":"3343_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00259-012-2251-4","volume":"40","author":"N Galldiks","year":"2013","unstructured":"Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging. 2013;40:22\u201333. doi: 10.1007\/s00259-012-2251-4 .","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3343-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3343-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3343-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:06:31Z","timestamp":1558699591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3343-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3343"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3343-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}